New Genetic Factor Explains Why Ozempic and Similar Drugs May Not Work for Some Individuals

A new study from Stanford Medicine and international collaborators has identified specific genetic variants that may cause approximately 10% of people to experience 'GLP-1 resistance,' making popular diabetes and weight-loss drugs like Ozempic and Wegovy less effective for them. These individuals produce higher levels of the GLP-1 hormone but do not respond to it properly. The study, which focused on blood sugar effects, was published March 29 in Genome Medicine and reported on April 12, 2026.

Context

The study conducted by Stanford Medicine and international collaborators highlights a significant barrier to the effectiveness of GLP-1 receptor agonists, such as Ozempic and Wegovy. Approximately 10% of individuals may not respond to these medications due to genetic differences. This research builds on existing knowledge of how genetics can impact drug metabolism and response.

Why it matters

Understanding genetic factors that influence drug effectiveness can improve personalized medicine. Identifying GLP-1 resistance helps tailor treatments for diabetes and obesity. This research may lead to better outcomes for those affected by these genetic variants.

Implications

Individuals with GLP-1 resistance may continue to struggle with diabetes management and weight loss despite medication. Healthcare systems may need to adjust approaches to treatment based on genetic testing. This discovery could influence drug development and clinical practices in treating metabolic disorders.

What to watch

Future research may explore additional genetic markers that influence drug efficacy. Monitoring how healthcare providers adapt treatment plans based on genetic testing will be important. The pharmaceutical industry may also respond by developing alternative therapies for those with GLP-1 resistance.